AdaptHealth Sells Diabetes Business to Cardinal Health for $235M
Event summary
- AdaptHealth Corp. agreed to sell its Diabetes Health business to Cardinal Health for $235 million in cash, subject to adjustments.
- The transaction is expected to close following regulatory review under the Hart-Scott-Rodino Antitrust Improvements Act.
- CEO Suzanne Foster framed the divestiture as part of a multi-year strategy to focus on core sleep and respiratory health businesses.
- AdaptHealth will treat Diabetes Health as discontinued operations post-divestiture.
The big picture
This divestiture marks a strategic pivot for AdaptHealth, aligning with broader industry consolidation trends as home healthcare providers streamline portfolios to focus on high-growth segments. Cardinal Health's acquisition reflects its push to expand in medical devices and chronic disease management, leveraging its distribution scale. The $235 million deal underscores the value of specialized diabetes care assets in a fragmented market.
What we're watching
- Capital Redeployment
- How AdaptHealth will allocate the $235 million proceeds to strengthen its balance sheet and accelerate growth in sleep and respiratory care.
- Regulatory Timing
- The pace at which the Hart-Scott-Rodino review progresses, given Cardinal Health's scale in healthcare distribution.
- Core Business Focus
- Whether AdaptHealth can sustain revenue growth and operational efficiency in its remaining sleep and respiratory segments post-divestiture.
Related topics